Source link : https://www.newshealth.biz/health-news/ema-authorizes-korjuny-for-malignant-ascites/
In its October 2024 meeting, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) gave the green light for Korjuny (catumaxomab, Lindis Biotech GmbH) to be used for the intraperitoneal treatment of malignant ascites in patients not eligible for further systemic anticancer therapy. The active substance of Korjuny is catumaxomab, a […]
Author : News Health
Publish date : 2024-10-18 14:07:22
Copyright for syndicated content belongs to the linked Source.
Categories